ICU Medical, Inc. (NASDAQ:ICUI) Receives $179.00 Consensus Price Target from Analysts

Key Points

• ICU Medical, Inc. has received a consensus recommendation of "Buy" from analysts, with an average 12-month price target of $179.00 based on coverage from five research firms.
• CEO Vivek Jain acquired 21,929 shares of ICU Medical at an average price of $112.84, increasing his stake by over 20%, while COO Christian B. Voigtlander sold 4,985 shares at an average price of $128.50.
• In its latest earnings report, ICU Medical reported an EPS of $2.10, surpassing estimates, though revenue was down 8.0% year-over-year at $543.57 million.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) has earned a consensus recommendation of "Buy" from the five brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $179.00.

Several research analysts recently issued reports on the stock. Raymond James Financial cut their target price on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. Wall Street Zen lowered shares of ICU Medical from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Piper Sandler assumed coverage on shares of ICU Medical in a research note on Friday, August 15th. They set an "overweight" rating and a $145.00 target price on the stock.

Insider Buying and Selling at ICU Medical

In other news, COO Christian B. Voigtlander sold 4,985 shares of the stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $128.50, for a total value of $640,572.50. Following the completion of the sale, the chief operating officer owned 6,088 shares in the company, valued at $782,308. This represents a 45.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Vivek Jain bought 21,929 shares of the stock in a transaction dated Thursday, August 14th. The stock was purchased at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer owned 130,149 shares of the company's stock, valued at $14,686,013.16. The trade was a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 14,889 shares of company stock worth $1,933,186. Corporate insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On ICU Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ICUI. Quarry LP boosted its position in shares of ICU Medical by 764.3% in the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock valued at $38,000 after acquiring an additional 214 shares during the period. Cullen Frost Bankers Inc. bought a new position in shares of ICU Medical in the second quarter valued at approximately $38,000. Russell Investments Group Ltd. boosted its position in shares of ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 300 shares during the period. Sterling Capital Management LLC boosted its position in shares of ICU Medical by 813.5% in the fourth quarter. Sterling Capital Management LLC now owns 676 shares of the medical instruments supplier's stock valued at $105,000 after acquiring an additional 602 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of ICU Medical by 27.2% in the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 153 shares during the period. Institutional investors own 96.10% of the company's stock.

ICU Medical Price Performance

Shares of ICU Medical stock traded down $1.0550 during midday trading on Friday, hitting $122.7050. 110,403 shares of the company traded hands, compared to its average volume of 267,413. The stock has a market cap of $3.03 billion, a price-to-earnings ratio of -80.73 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The firm's fifty day moving average price is $127.68 and its 200-day moving average price is $137.63. ICU Medical has a 12 month low of $107.00 and a 12 month high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, topping analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $543.57 million for the quarter, compared to analyst estimates of $543.33 million. During the same period in the previous year, the firm posted $1.56 EPS. The company's revenue for the quarter was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, sell-side analysts forecast that ICU Medical will post 4.11 earnings per share for the current year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.